Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3074-3084

  Nanjundan, Meera ^a   Nakayama, Yasuhisa ^a,e   Kwai, Wa Cheng ^a   Lahad, John ^a   Liu, Jinsong ^a   Lu, Karen ^a   Kuo, Wen Lin ^b   Smith McCune, Karen ^c   Fishman, David ^d   Gray, Joe W ^b   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROTEIN ECOTROPIC VIRAL INTEGRATION SITE 1; PROTEIN MYELODYSPLASTIC SYNDROME 1; UNCLASSIFIED DRUG; DNA; DNA BINDING PROTEIN; EVI1 PROTEIN, HUMAN; MESSENGER RNA; TRANSCRIPTION FACTOR;

AMPLICON; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; BIOSYNTHESIS; CANCER STAGING; CHROMOSOME 3; EPITHELIUM CELL; FEMALE; GENE DOSAGE; GENETICS; METABOLISM; NUCLEIC ACID HYBRIDIZATION; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROTEIN TERTIARY STRUCTURE; PROTO ONCOGENE; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 3; DNA, NEOPLASM; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; NEOPLASM STAGING; NUCLEIC ACID HYBRIDIZATION; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENES; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 34248219165     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2366     Document Type: Article

References (46)

1. Sugita M, Tanaka N, Davidson S, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung Cancer Genet Cytogenet 2000;117:9-18.
2. Imoto I, Yuki Y, Sonoda I, et al. Identification of ZASC1 encoding a Kruppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. Cancer Res 2003;63:5691-6.
3. Imoto I, Pimkhaokham A, Fukuda Y, et al. SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem Biophys Res Commun 2001;286:559-65.
4. Riazimand SH, Welkoborsky HJ, Bernauer HS, Jacob R, Mann WJ. Investigations for fine mapping of amplifications in chromosome 3q26.3-28 frequently occurring in squamous cell carcinomas of the head and neck. Oncology 2002;63:385-92.
5. Sattler UP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 1999;39:79-86.
6. Sattler HP, Lensch R, Rohde V, et al. Novel amplification unit at chromosome 3q25-27 in human prostate cancer. Prostate 2000;45:207-15.
7. Weber-Mangal S, Sinn HP, Popp S, et al. Breast cancer in young women (< or = 35 years): genomic aberrations detected by comparative genomic hybridization. Int J Cancer 2003;107:583-92.
8. Wessels LF, van Welsem T, Hart AA, van't Veer LJ, Reinders MJ, Nederlof PM. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002;62:7110-7.
9. Or YY, Hui AB, Tam KY, Huang DP, Lo KW. Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol 2005; 26:49-56.
10. Casas S, Aventin A, Fuentes F, et al. Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia Cancer Genet Cytogenet 2004;153:16-25.
11. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
12. Eder AM, Sui X, Rosen DG, et al. Atypical PKCι contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:12519-24.
13. Zhang L, Huang J, Yang N, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCι as a biomarker and potential oncogene in ovarian carcinoma Cancer Res 2006;66:4627-35.
14. Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase Cι is an oncogene in human non-small cell lung cancer. Cancer Res 2005;65:8905-11.
15. Guan XY, Fung JM, Ma NF, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res 2004;64:4197-200.
16. Estilo CL, O-Charoenrat P, Ngai I, et al. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110α in squamous cell carcinoma of the oral tongue. Clin Cancer Res 2003;9:2300-6.
17. Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T, Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res 2003;9:4705-13.
18. Sunde JS, Donninger H, Wu K, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-β signaling in ovarian cancer. Cancer Res 2006;66: 8404-12.
19. Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders: history and perspectives. Gene 2006;368:1-11.
20. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFβ- and taxol-mediated cell death via PI3K/AKT. Oncogene 2006;25:3565-75.
21. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4.
22. Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol 2001;114:566-73.
23. Kurokawa M, Mitani K, Irie K, et al. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature 1998;394:92-6.
24. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 1994;269: 24020-6.
25. Morishita K, Parganas E, Douglass EC, Ihle JN. Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene 1990;5:963-71.
26. Brooks DJ, Woodward S, Thompson FH, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 1996;74:1518-25.
27. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003;101:837-45.
28. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004;296:151-62.
29. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia 1999;13:348-57.
30. Soderholm J, Kobayashi H, Mathieu C, Rowley JD, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia 1997;11:352-8.
31. Vinatzer U, Mannhalter C, Mitterbauer M, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 2003;36: 80-9.
32. Steele-Perkins G, Fang W, Yang XH, et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein- methyltransferase superfamily. Genes Dev 2001;15:2250-62.
33. Chi Y, Senyuk V, Chakraborty S, Nucifora G. EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity. J Biol Chem 2003;278:49806-11.
34. Nitta E, Izutsu K, Yamaguchi Y, et al. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene 2005;24: 6165-73.
35. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Lowenberg B, Delwel R. Low expression of MDS1-1-like-1 (MEL1) and EVI1-like-I (EL1) genes in favorable-risk acute myeloid leukemia. Exp Hematol 2003;31:1066-72.
36. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma Nat Med 2002;8:816-24.
37. Maldonado JL, Timmerman L, Fridlyand J, Bastian BC. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol 2004;164:1783-7.
38. Campbell IG, Russell SE, Phillips WA. PIK3CA mutations in ovarian cancer. Clin Cancer Res 2005;11: 7042; author reply 42-3.
39. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL. PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 2005;25:322.
40. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
41. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8.
42. Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K, Matsuoka M. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood 2004;103: 2753-60.
43. Elliott RL, Blobe GC. Role of transforming growth factor β in human cancer. J Clin Oncol 2005;23:2078-93.
44. Yatsula B, Lin S, Read AJ, et al. Identification of binding sites of EVI1 in mammalian cells. J Biol Chem 2005;280:30712-22.
45. Louz D, van den Broek M, Verbakel S, et al. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia 2000;14: 1876-84.
46. Frankel A, Yadav N, Lee J, Branscombe TL, Clarke S, Bedford MT. The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem 2002;277: 3537-43.